[
    [
        {
            "time": "2018-09-24",
            "original_text": "Lilly's Elanco animal health unit's IPO priced at $24/share",
            "features": {
                "keywords": [
                    "Elanco",
                    "IPO",
                    "priced",
                    "$24/share"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's Elanco animal health unit's IPO priced at $24/share",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Elanco Animal Health prices IPO above expected range",
            "features": {
                "keywords": [
                    "Elanco",
                    "Animal Health",
                    "prices",
                    "IPO",
                    "above",
                    "expected range"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Elanco Animal Health prices IPO above expected range",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Elanco Announces Pricing of Initial Public Offering",
            "features": {
                "keywords": [
                    "Elanco",
                    "Pricing",
                    "Initial Public Offering"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Elanco Announces Pricing of Initial Public Offering",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "J&J Files NDA for Erdafitinib in Urothelial Cancer Indication",
            "features": {
                "keywords": [
                    "J&J",
                    "NDA",
                    "Erdafitinib",
                    "Urothelial Cancer"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "J&J Files NDA for Erdafitinib in Urothelial Cancer Indication",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO",
            "features": {
                "keywords": [
                    "Lilly",
                    "Elanco",
                    "Rises",
                    "$1.5 Billion",
                    "Animal-Health",
                    "IPO"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-24",
            "original_text": "Lilly's Elanco Raises $1.5 Billion in Animal-Health IPO",
            "features": {
                "keywords": [
                    "Lilly",
                    "Elanco",
                    "Raises",
                    "$1.5 Billion",
                    "Animal-Health",
                    "IPO"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's Elanco Raises $1.5 Billion in Animal-Health IPO",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-23",
            "original_text": "Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates",
            "features": {
                "keywords": [
                    "Pharma Stocks",
                    "Pfizer",
                    "Revenue Trend",
                    "2018 Estimates"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-08-15",
            "original_text": "Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Restructure",
                    "R&D Unit",
                    "Lay Off",
                    "400 Staff"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-10",
            "original_text": "Pharma Stocks in Review: A Valuation Comparison",
            "features": {
                "keywords": [
                    "Pharma Stocks",
                    "Valuation Comparison"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pharma Stocks in Review: A Valuation Comparison",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]